孟鲁司特治疗及预防2～5岁儿童哮喘的疗效观察

目的 观察孟鲁司特在2～5岁儿童哮喘防治中的效果.方法 66例2～5岁学龄前哮喘患儿完全随机分为治疗组与对照组,各33例.治疗组在常规治疗的基础上加用孟鲁司特,对照组给予辅舒酮气雾吸入,疗程均3个月.结果 急性发作期治疗组疗效优于对照组症状缓解时间:(4.26±1.57)d比(5.83±1.62)d;肺部体征消失时间:(3.84±1.31)d比(5.25±1.12)d;P＜0.01];急性发作期治疗后患儿外周血嗜酸粒细胞计数治疗组较对照组降低(0.36±0.12)×109/L比(0.51±0.15)×109/L],差异有统计学意义(P＜0.05);治疗组较对照组复发次数少、无症状时间长、再次发作的病情轻(均P＜0.05).结论 孟鲁司特依从性好,对于2～5岁学龄前儿童轻中度哮喘治疗及预防疗效显著.

Abstract：

Objective To explore the curative and preventive effect of montelukast in 2-5 years old asthmatic children. Motheds Sixty-six cases were randomly assigned as group A (were treated with fluticasone propionate inhalation) and group B (were administrated orally at montelukast). They were treated with routine treatment.The total course of two groups were three month. Results The curative effect of group B was significantly better than that of group A in acute attack of asthmatic children. The relapse, sympto-matic stage, relapse pathocure of group B were significantly better than that of group A. There was significant difference between treatment before and treatment after (symptoms disappearing) that EC of asthmatic children( P ＜0.05 ), There were some differences between group B ahd group A that there were less times that symptoms appeared after treatment. It was a long time that symptoms disappeared. Conclusion The clinical experiments show that montelukast has dramatic efficacy for the 2-5 years old children with low-grade or moderate asthma without any side effects.

The observation of curative and preventive effect of montelukast in 2-5 years old asthmatic children

Objective To explore the curative and preventive effect of montelukast in 2-5 years old asthmatic children. Motheds Sixty-six cases were randomly assigned as group A (were treated with fluticasone propionate inhalation) and group B (were administrated orally at montelukast). They were treated with routine treatment.The total course of two groups were three month. Results The curative effect of group B was significantly better than that of group A in acute attack of asthmatic children. The relapse, sympto-matic stage, relapse pathocure of group B were significantly better than that of group A. There was significant difference between treatment before and treatment after (symptoms disappearing) that EC of asthmatic children( P ＜0.05 ), There were some differences between group B ahd group A that there were less times that symptoms appeared after treatment. It was a long time that symptoms disappeared. Conclusion The clinical experiments show that montelukast has dramatic efficacy for the 2-5 years old children with low-grade or moderate asthma without any side effects.